Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
HLS Therapeutics and Esperion partner
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
FDA plans to expand unannounced inspections of foreign drug plants
The US Food and Drug Administration (FDA) is moving to tighten oversight of foreign manufacturers supplying the US market by subjecting overseas facilities to unannounced inspections, which ha...
Preclinical Data on First-in-Class BTK SH2
Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria
Takeda Pledges $30B in U.S., Argues Against Trump’s
Takeda Pledges $30B in U.S., Argues Against Trump’s ‘Most Favored Nations’ Proposal
Aptevo Therapeutics Provides Program Update for Bispecific APVO711 ( PD-L1 х CD40)
Aptevo Therapeutics Provides Program Update for Bispecific APVO711 ( PD-L1 х CD40) that Combines a Checkpoint Inhibitor and Immune Activation
Sanofi exec tells biotechs not to scrimp on clinical trial design
It is vital for biotech companies to run the right clinical trial and not cut costs with trial design or patient recruitment, the executive said.
AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use
AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved by the European Commission (EC) as part o...
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma-specific ones.
Preclinical study reveals how alcohol promotes fat buildup in liver
Cedars-Sinai investigators have discovered a signaling interaction between two proteins in cells that controls fat accumulation in the livers of laboratory mice with alcohol-associated liver disease.
Chinese regulator grants priority review for InnoCare’s solid tumour treatment
A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and efficacy in a registration trial.
31
32
33
34
35
36
37
38
39
